Kimball Electronics (KE) Company presentation summary
Event summary combining transcript, slides, and related documents.
Company presentation summary
20 Mar, 2026Company overview and strategic positioning
Global provider of electronics manufacturing and contract manufacturing services with a diversified portfolio in automotive, medical, and industrial markets, supported by long program life cycles.
Specializes in high-complexity, non-commodity manufacturing requiring advanced engineering and reliability.
Operates 7 manufacturing locations across North America, Europe, and Asia, with over 5,500 employees and $1.49B in FY25 revenue.
Core values emphasize customer focus, people, environmental citizenship, and profit as a measure of efficiency.
Integrated service platform and capabilities
Offers end-to-end services: design, prototyping, new product introduction, manufacturing, testing, and aftermarket support.
EMS includes PCB assembly, system assembly, prototyping, supply chain management, and design engineering.
CMO focuses on medical solutions, including scientific injection molding, cold chain management, and complex device assembly.
Market verticals and customer base
Revenue split in FY25: 49% automotive, 27% medical, 24% industrial.
Automotive growth driven by vehicle electrification and electronic content; key customers include Tier 1 suppliers.
Medical segment supports the continuum of care, focusing on Class II and III devices for leading healthcare brands.
Industrial segment targets clean energy, automation, and public safety, with diversification into new sub-verticals.
Latest events from Kimball Electronics
- Q4 growth and margin gains set up a 7–9% FY27 outlook, driven by medical and Helvoet.KE
Q4 2026 - Medical segment growth and new facility drive raised outlook and margin expansion plans.KE
2026 KeyBanc Capital Markets Healthcare Forum - Acquisition expands global medical CMO platform, boosting growth and earnings by 2027.KE
M&A announcement - Profitable growth expected as medical and automotive markets drive margin expansion and investment.KE
Company presentation - Medical-led sequential growth and strong margins support high-end fiscal 2026 outlook.KE
Q3 2026 - Q2 sales fell 5% but margins and 2026 guidance improved on strong medical growth.KE
Q2 2026 - Q1 FY2025 sales fell 15% as restructuring and asset sales improved cash flow and reduced debt.KE
Q1 2025 - Q4 sales dropped 13% as inventory and liquidity improved; 2025 outlook remains cautious.KE
Q4 2024 - Streamlined operations and global focus drive resilience despite EMS market headwinds.KE
The Stifel 2024 Cross Sector Insight Conference